`Date filed: November 14, 2018
`
`Filed On Behalf Of:
`Novartis Pharmaceuticals Corporation
`
`By:
`Nicholas N. Kallas
`NKallas@Venable.com
`ZortressAfinitorIPR@Venable.com
`(212) 218-2100
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`WEST-WARD PHARMACEUTICALS INTERNATIONAL LIMITED,
`
`Petitioner,
`
`v.
`
`NOVARTIS PHARMACEUTICALS CORPORATION,
`
`Patent Owner.
`
`IPR2017-015921
`Patent No. 8,410,131 B2
`
`PATENT OWNER’S THIRD UPDATED MANDATORY
`NOTICES UNDER 37 C.F.R. § 42.8(a)(3)
`
`1 IPR2018-00507 has been joined to this proceeding.
`
`
`
`Pursuant to the requirements of 37 C.F.R. § 42.8(a)(3), Novartis
`
`Pharmaceuticals Corporation (“Novartis” or “Patent Owner”) submits the
`
`following update to its July 24, 2018 Second Updated Mandatory Notices (Paper
`
`No. 49).
`
`REAL PARTY-IN-INTEREST PURSUANT TO 37 C.F.R. § 42.8(b)(1)
`
`The real party-in-interest information has not changed.
`
`RELATED MATTERS PURSUANT TO 37 C.F.R. § 42.8(b)(2)
`
`The related matters information has not changed.
`
`IDENTIFICATION OF LEAD AND BACK-UP COUNSEL
`PURSUANT TO 37 C.F.R. §§ 42.8(b)(3) and 42.10
`
`The lead and back-up counsel have not changed, however, Novartis reports a
`
`change of firm name for lead and back-up counsel from Fitzpatrick, Cella, Harper
`
`& Scinto to Venable LLP. The contact information for lead and back-up counsel
`
`has changed as follows:
`
`Lead Counsel
`
`Back-Up Counsel
`
`Back-Up Counsel
`
`Nicholas N. Kallas (Reg. No. 31,530)
`VENABLE LLP
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`NKallas@Venable.com
`Laura K. Fishwick (Reg. No. 69,907)
`VENABLE LLP
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`LFishwick@Venable.com
`Christina Schwarz (admitted pro hac vice)
`
`1
`
`
`
`Back-Up Counsel
`
`VENABLE LLP
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`CSchwarz@Venable.com
`Jared L. Stringham (admitted pro hac vice)
`VENABLE LLP
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`JLStringham@Venable.com
`
`SERVICE INFORMATION PURSUANT TO 37 C.F.R. § 42.8(b)(4)
`
`The service information for counsel for Novartis has changed. Novartis may
`
`be served electronically using the following e-mail address:
`
`ZortressAfinitorIPR@Venable.com
`
`Novartis may be served by postal mailing, hand-delivery, telephone or
`
`facsimile as follows:
`
`Respectfully submitted,
`
`Dated: November 14, 2018
`
`Nicholas N. Kallas
`Venable LLP
`1290 Avenue of the Americas
`New York, NY10104
`Telephone: (212) 218-2100
`Facsimile: (212) 218-2200
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`Lead Counsel for Patent Owner
`
`2
`
`
`
`VENABLE LLP
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`3
`
`
`
`CERTIFICATE OF SERVICE
`
`I certify that a copy of Patent Owner’s Third Updated Mandatory Notices
`
`Under 37 C.F.R. § 42.8(a)(3) was served on November 14, 2018 by causing it to be
`
`sent by email to counsel for Petitioner at the following email addresses:
`
`Keith A. Zullow (kzullow@goodwinprocter.com)
`
`Marta E. Delsignore (mdelsignore@goodwinprocter.com)
`
`Michael Cottler (mcottler@goodwinlaw.com)
`
`Dated: November 14, 2018
`
`/ Nicholas N. Kallas /
`Nicholas N. Kallas
`Registration No. 31,530
`VENABLE LLP
`1290 Avenue of the Americas
`New York, NY 10104-3800
`Tel. 212-218-2100
`
`4
`
`